RBC Capital announced Sarepta Therapeutics (NASDAQ:SRPT), stepping up its price target to $83.00 earlier today
- Updated: September 19, 2016
In a report announced on 9/19/2016 RBC Capital upped the target price of Sarepta Therapeutics (NASDAQ:SRPT) from $5 to $83 indicating a possible upside of 1.95%.
On 7/22/2016, Needham reported about Sarepta Therapeutics(NASDAQ:SRPT) bumped the target price from $20.00 to $26.00. At the time, this indicated a possible upside of 0.15%.
Boasting a price of $28.15, Sarepta Therapeutics (NASDAQ:SRPT) traded 91.30% higher on the day. The last stock close is up 163.13% from the 200-day moving average, compared to the S&P 500 which has fallen -0.01% over the same time. SRPT has registered a 50-day average of $26.16 and 200-day average of $20.47. Trading volume was was up over the average, with 29,541,278 shares of SRPT changing hands over the typical 2,328,380 shares.
Recent Performance Graphic:
Sarepta Therapeutics has a one-year low of $8.00 and a 52 week high of $56.18 . SRPT’s total market value is currently $0.0.
Also covering Sarepta Therapeutics’s stock price target, a total of 13 equity analysts have released a research note on the stock. The one year target is $20.77 with three firms rating the company a strong buy, one analyst rating the company a buy, five analyts rating the stock a hold, four firms rating the stock to underperform, and finally one firmrating the stock as sell.
Brief Synopsis On Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.